<!-- Content: General Sarcoma -->
<div class="content-container">
  <!-- Featured Publication -->
  <section id="featured-publication" class="section">
    <h2 class="section-title gradient-text">Featured Publication</h2>
    <div class="card pub-card">
      <div class="pub-media">
        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924026/" target="_blank" rel="noopener">
          <img src="https://leiomyosarcoma.info/wp-content/uploads/2021/03/Cancers.png" alt="Cancers Journal" />
        </a>
      </div>
      <div class="pub-body">
        <h3 class="pub-title">
          <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924026/" target="_blank" rel="noopener">
            NLMSF–SPAEN publication on evidence‑based unmet needs in LMS research and treatment
          </a>
        </h3>
        <p class="muted">A collaborative paper highlighting critical gaps and priorities to accelerate progress in leiomyosarcoma research and care.</p>
      </div>
    </div>
  </section>

  <!-- Research Grants -->
  <section id="research-grants" class="section">
    <h2 class="section-title gradient-text">NLMSF Research Grants</h2>
    <div class="card">
      <h3 class="card-title">2026–2027 Research Grant Announcement</h3>
      <p><strong>LOI deadline:</strong> April 15, 2025</p>
      <p>
        The National Leiomyosarcoma Foundation (NLMSF) invites letters of intent (LOIs) for pilot studies to launch new research trajectories in LMS, with a focus on basic and translational science. Clinical interventional trials are out of scope.
      </p>
      <ul class="checklist">
        <li>Total award: $50,000 per year for 2 years (indirects ≤ 10%).</li>
        <li>Scope includes biomarkers, imaging, computational biology, radiomics, and lab‑based translational studies.</li>
        <li>Human sample studies require IRB approval (or waiver) prior to award.</li>
      </ul>
      <p class="muted">
        Submission contacts: matthew.hemming@umassmemorial.org and alessandra.maleddu@cuanschutz.edu
      </p>
    </div>
  </section>

  <!-- Research Updates -->
  <section id="research-updates" class="section">
    <h2 class="section-title gradient-text">Research Updates</h2>
    <div class="updates-list">
      <article class="update-item">
        <h4 class="update-title">
          <a href="https://pubmed.ncbi.nlm.nih.gov/40543045/" target="_blank" rel="noopener">
            Stereotactic radiosurgery outcomes for brain metastases from sarcoma primaries (2025)
          </a>
        </h4>
        <p class="muted">International multicenter analysis; Cancer (2025).</p>
      </article>
      <article class="update-item">
        <h4 class="update-title">
          <a href="https://www.sciencedirect.com/science/article/abs/pii/S0889858825000450?via%3Dihub" target="_blank" rel="noopener">
            Leiomyosarcoma: Therapeutic approaches and future directions (2025)
          </a>
        </h4>
        <p class="muted">Hematology/Oncology Clinics of North America.</p>
      </article>
      <article class="update-item">
        <h4 class="update-title">
          <a href="https://pubmed.ncbi.nlm.nih.gov/40358615/" target="_blank" rel="noopener">
            Trabectedin + Olaparib Phase II trial in advanced sarcoma (2025)
          </a>
        </h4>
        <p class="muted">Clin Cancer Res. Online ahead of print.</p>
      </article>
    </div>
    <p class="more-link">
      For additional items, see our News Tracker and Clinical Trials pages.
    </p>
  </section>

  <!-- Clinical Trials & Education -->
  <section id="trials-education" class="section">
    <h2 class="section-title gradient-text">Clinical Trials & Education</h2>
    <ul class="resource-list">
      <li>
        <a class="resource-link" href="https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS11590" target="_blank" rel="noopener">
          Lurbinectedin + doxorubicin vs doxorubicin (metastatic LMS) — Study overview
        </a>
      </li>
      <li>
        <a class="resource-link" href="https://www.ncbi.nlm.nih.gov/books/NBK551667/" target="_blank" rel="noopener">
          Leiomyosarcoma — Continuing Education (NCBI Bookshelf)
        </a>
      </li>
      <li>
        <a class="resource-link" href="https://www.frontiersin.org/articles/10.3389/fonc.2023.1149106/full" target="_blank" rel="noopener">
          Therapeutic advances in leiomyosarcoma (Frontiers in Oncology)
        </a>
      </li>
      <li>
        <a class="resource-link" href="https://www.onclive.com/view/annamycin-drives-clinical-benefit-in-soft-tissue-sarcoma-lung-metastases" target="_blank" rel="noopener">
          Annamycin drives clinical benefit in soft tissue sarcoma lung metastases (OncLive)
        </a>
        <p class="muted" style="margin: 4px 0 0;">
          Phase 1b/2 MB‑107: next‑gen anthracycline annamycin showed a 59.4% clinical benefit rate (n=36) with median OS 13.5 months in phase 2 (330 mg/m²).
          Patients achieving response or stable disease after 2 cycles had median OS 19.7 months; no cardiotoxicity reported across cohorts.
        </p>
      </li>
    </ul>
  </section>

  <!-- Research Library (By Year) -->
  <section id="research-library" class="section">
    <h2 class="section-title gradient-text">Research Library (By Year)</h2>

    <!-- 2025 -->
    <div class="year-section">
      <h3 class="year-title">2025</h3>
      <ul class="resource-list">
        <li>
          <a class="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/40543045/" target="_blank" rel="noopener">Clinical outcomes following stereotactic radiosurgery for brain metastases from sarcoma primaries (Cancer, 2025)</a>
        </li>
        <li>
          <a class="resource-link" href="https://www.sciencedirect.com/science/article/abs/pii/S0889858825000450?via%3Dihub" target="_blank" rel="noopener">Leiomyosarcoma: Therapeutic Approaches and Future Directions (H/O Clinics of North America)</a>
        </li>
        <li>
          <a class="resource-link" href="https://www.sciencedirect.com/science/article/abs/pii/S0889858825000401?via%3Dihub" target="_blank" rel="noopener">Emerging Role of Blood‑based Biomarkers in Sarcomas (H/O Clinics of North America)</a>
        </li>
        <li>
          <a class="resource-link" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12652729/" target="_blank" rel="noopener">MicroRNAs in Uterine Leiomyosarcoma: From Molecular Mechanisms to Clinical Applications (Int J Mol Sci. 2025;26(22):10952)</a>
          <p class="muted">Kourti A, Kalogiannidis I, Makedou K, Georgiou E. doi: 10.3390/ijms262210952. Full research publication available via PubMed Central.</p>
        </li>
        <li>
          <a class="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/40358615/" target="_blank" rel="noopener">Trabectedin + Olaparib in Advanced Sarcoma — Phase II Multicenter Trial (Clin Cancer Res)</a>
        </li>
        <li>
          <a class="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/40357995/" target="_blank" rel="noopener">Histology‑driven tailoring of surgery in retroperitoneal STS (BJS Open, 2025)</a>
        </li>
        <li>
          <a class="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/40230424/" target="_blank" rel="noopener">Myxoid Leiomyosarcoma of the Uterus — Case Report (Oncology Letters, 2025)</a>
        </li>
      </ul>
    </div>

    <!-- 2024 -->
    <div class="year-section">
      <h3 class="year-title">2024</h3>
      <ul class="resource-list">
        <li>
          <a class="resource-link" href="https://www.nejm.org/doi/full/10.1056/NEJMc2412479" target="_blank" rel="noopener">Doxorubicin–Trabectedin in Leiomyosarcoma (NEJM correspondence)</a>
        </li>
        <li>
          <a class="resource-link" href="https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS11590" target="_blank" rel="noopener">Lurbinectedin + doxorubicin vs doxorubicin alone — metastatic LMS (JCO TPS11590)</a>
        </li>
        <li>
          <a class="resource-link" href="https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2024.1375483/full" target="_blank" rel="noopener">Leiomyosarcoma of the abdomen and retroperitoneum — systematic review (Frontiers in Surgery)</a>
        </li>
        <li>
          <a class="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/39356980" target="_blank" rel="noopener">Phase Ib: Doxorubicin, Dacarbazine, and Nivolumab (GEIS) — LMS (JCO)</a>
        </li>
        <li>
          <a class="resource-link" href="https://ascopubs.org/doi/10.1200/EDBK_432234" target="_blank" rel="noopener">Immunotherapy in Sarcoma: Current Data and Promising Strategies (ASCO Educational Book)</a>
        </li>
        <li>
          <a class="resource-link" href="https://doi.org/10.1158/1078-0432.CCR-24-0148" target="_blank" rel="noopener">Developing Novel Genomic Risk Stratification Models in STS & ULMS (Clin Cancer Res)</a>
        </li>
        <li>
          <a class="resource-link" href="https://www.ncbi.nlm.nih.gov/books/NBK551667/" target="_blank" rel="noopener">Leiomyosarcoma — Continuing Education Activity (NCBI Bookshelf)</a>
        </li>
      </ul>
    </div>

    <!-- 2023 -->
    <div class="year-section">
      <h3 class="year-title">2023</h3>
      <ul class="resource-list">
        <li><a class="resource-link" href="https://www.frontiersin.org/articles/10.3389/fonc.2023.1149106/full" target="_blank" rel="noopener">Therapeutic advances in leiomyosarcoma (Frontiers in Oncology)</a></li>
        <li><a class="resource-link" href="https://www.mdpi.com/2072-6694/15/7/2099" target="_blank" rel="noopener">Targeting Molecular and Immunologic Features of LMS (Cancers)</a></li>
        <li><a class="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/36603130/" target="_blank" rel="noopener">Sequential RB and DNA synthesis pathway targeting strategy (MD Anderson)</a></li>
        <li><a class="resource-link" href="https://link.springer.com/article/10.1007/s11864-023-01067-2" target="_blank" rel="noopener">Not All Leiomyosarcomas Are the Same: classification (Springer)</a></li>
        <li><a class="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/36857355/" target="_blank" rel="noopener">Trabectedin long‑term disease control retrospective study</a></li>
        <li><a class="resource-link" href="https://doi.org/10.1093/oncolo/oyad052" target="_blank" rel="noopener">Emerging Trends in Immunotherapy for Adult Sarcomas (The Oncologist)</a></li>
      </ul>
    </div>

    <!-- 2022 -->
    <div class="year-section">
      <h3 class="year-title">2022</h3>
      <ul class="resource-list">
        <li><a class="resource-link" href="https://onlinelibrary.wiley.com/doi/full/10.1002/ctd2.149" target="_blank" rel="noopener">Molecular subtypes of leiomyosarcoma: Toward consensus</a></li>
        <li><a class="resource-link" href="https://link.springer.com/article/10.1245/s10434-022-12517-w" target="_blank" rel="noopener">Landmark studies in primary localized retroperitoneal sarcoma</a></li>
        <li><a class="resource-link" href="https://aacrjournals.org/clincancerres/article-abstract/28/15/3225/707113/" target="_blank" rel="noopener">Eribulin–Gemcitabine in LPS/LMS Phase II</a></li>
        <li><a class="resource-link" href="https://www.nature.com/articles/s41598-022-16055-z" target="_blank" rel="noopener">Retroperitoneal LMS nomogram model</a></li>
        <li><a class="resource-link" href="https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-22-0738/694390/" target="_blank" rel="noopener">ctDNA for LMS recurrence monitoring</a></li>
        <li><a class="resource-link" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029111/" target="_blank" rel="noopener">Preoperative differentiation of leiomyomas vs leiomyosarcomas</a></li>
      </ul>
    </div>

    <!-- 2020 -->
    <div class="year-section">
      <h3 class="year-title">2020</h3>
      <ul class="resource-list">
        <li><a class="resource-link" href="http://pubmed.ncbi.nlm.nih.gov/32211860" target="_blank" rel="noopener">Nutrition & gut microbiome — current explorations</a></li>
        <li><a class="resource-link" href="https://www.onclive.com/view/sarcoma-experts-elucidate-on-combination-chemotherapy-regimens" target="_blank" rel="noopener">Combination chemotherapy regimens — expert review</a></li>
        <li><a class="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/31439678/" target="_blank" rel="noopener">Genomic profiling of primary histiocytic sarcoma</a></li>
        <li><a class="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/32299819/" target="_blank" rel="noopener">Genomic landscape of uterine sarcomas (prospective sequencing)</a></li>
        <li><a class="resource-link" href="https://www.onclive.com/view/nbtxr3-activity-in-soft-tissue-sarcoma-could-be-replicated-in-other-cancers" target="_blank" rel="noopener">NBTXR3 activity in STS</a></li>
      </ul>
    </div>

    <!-- 2019 -->
    <div class="year-section">
      <h3 class="year-title">2019</h3>
      <ul class="resource-list">
        <li><a class="resource-link" href="https://pubmed.ncbi.nlm.nih.gov/31164371/" target="_blank" rel="noopener">Genomic Evolutionary Patterns of LMS & LPS (Clin Cancer Res)</a></li>
        <li><a class="resource-link" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656468/" target="_blank" rel="noopener">BRCA1/2 functional loss as a targetable subset in LMS</a></li>
        <li><a class="resource-link" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380497/" target="_blank" rel="noopener">ctDNA detection in progressive LMS</a></li>
      </ul>
    </div>

    <!-- 2018 -->
    <div class="year-section">
      <h3 class="year-title">2018</h3>
      <ul class="resource-list">
        <li><a class="resource-link" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759317/" target="_blank" rel="noopener">Soft Tissue and Uterine Leiomyosarcoma (review)</a></li>
        <li><a class="resource-link" href="https://www.ncbi.nlm.nih.gov/pubmed/31068995" target="_blank" rel="noopener">Cutaneous LMS on the trunk — aggressive course case & review</a></li>
        <li><a class="resource-link" href="https://www.sciencedirect.com/science/article/pii/S0147027217301757" target="_blank" rel="noopener">Ifosfamide and doxorubicin in advanced LMS</a></li>
      </ul>
    </div>

    <p class="muted" style="margin-top: 10px;">Note: This library highlights selections from a larger set you provided. If you want every item included verbatim, I can import them all and add year toggles.</p>
  </section>

  <!-- Full Research Archive (Verbatim) -->
  <section id="full-research-archive" class="section">
    <h2 class="section-title gradient-text">Full Research Archive (Verbatim)</h2>
    <p class="muted">Imported exactly as provided to ensure every original item appears. Collapsed by default for readability.</p>
    <details class="raw-archive">
      <summary>View full archive</summary>
      <div class="raw-archive-inner">
        <div class="elementor-widget-wrap">
          <div class="elementor-element elementor-element-60de566 elementor-widget elementor-widget-text-editor" data-id="60de566" data-element_type="widget" data-widget_type="text-editor.default">
            <div class="elementor-widget-container">
              <div class="elementor-text-editor elementor-clearfix"></div>
            </div>
          </div>
          <div class="elementor-element elementor-element-1970cb7 elementor-widget elementor-widget-text-editor" data-id="1970cb7" data-element_type="widget" data-widget_type="text-editor.default">
            <div class="elementor-widget-container">
              <div class="elementor-text-editor elementor-clearfix">
                <h1><img fetchpriority="high" decoding="async" src="https://leiomyosarcoma.info/wp-content/uploads/2024/08/NLMSF-Logo-Updated-30-Apr-2023-300x297.png" alt="" width="300" height="297">NATIONAL LEIOMYOSARCOMA FOUNDATION</h1>
                <h1>2026-2027 RESEARCH GRANT ANNOUNCEMENT</h1>
                <div>
                  <h1 style="font-weight: 400;"><strong>NLMSF Empowering patients through information / education / support</strong></h1>
                </div>
                <p><strong>LOI deadline: April 15<sup>th</sup>, 2025</strong></p>
                <p>Please submit to Matthew Hemming, M.D., PhD.: <a href="mailto:matthew.hemming@umassmemorial.org">matthew.hemming@umassmemorial.org</a> and <span>Alessandra Maleddu M.D.: </span><a href="mailto:alessandra.maleddu@cuanschutz.edu">alessandra.maleddu@cuanschutz.edu</a></p>
                <p><strong>Introduction</strong>: The National Leiomyosarcoma Foundation (NLMSF) is dedicated to meeting the needs of leiomyosarcoma (LMS) patients, caregivers and families through education and research. In order to facilitate advances in the treatment of LMS through research, the NLMSF is accepting research proposals for pilot studies that will launch “out of the box” ideas and new research trajectories to move the field forward.</p>
                <p><strong>Scope of the award/ areas of interest</strong>: All direct funds must be used to support LMS research. Proposals involving any scientific discipline are allowed including those related to biomarkers and imaging. This award was created to support basic and translational research. Other highly translational projects that are not based in a traditional wet lab may be considered (for example: <em>in silico</em> computational biology, radiomics, etc.); however, investigators who are considering submitting a non-traditional research project are highly encouraged to discuss the appropriateness of their project ahead of time. Clinical research (interventional trials) will not be supported by this award; however, work studying human samples and annotated data sets obtained from clinical trials is allowed. Studies requiring human samples must show documentation of IRB approval prior to awarding of funds (or document waivers if applicable).</p>
                <p><strong>Letter of Intent (LOI) Overview</strong>: The NLMSF seeks LOIs for research grant funding. The total award will be $50,000 per year for 2 years. Indirect costs should not exceed 10% of the total budget.<br>The LOI should consist of:<br>1) Proposed research (2 page maximum)<br>2) Applicant NIH Biosketch</p>
                <p><strong><em>Key Dates:</em></strong><br>LOI due: April 15<sup>th</sup>, 2025<br>Invitations for full proposal sent: May 30<sup>th</sup>, 2025<br>Full proposal due: August 31<sup>st</sup>, 2025<br>Announcement: November 2025<br>Funding start date: January 2026</p>
                <p>_____________________________________________________________________________________________________________________</p>
                <h1>2025</h1>
                <h3 class="heading-title">Clinical outcomes following stereotactic radiosurgery for brain metastases from sarcoma primaries: An international multicenter analysis (Cancer. 2025 Jul 1;131(13):e35931. doi: 10.1002/cncr.35931.)</h3>
                <div><a href="https://pubmed.ncbi.nlm.nih.gov/40543045/" target="_blank" rel="noopener">https://pubmed.ncbi.nlm.nih.gov/40543045/</a></div>
                <p><span class="title-text">Leiomyosarcoma Therapeutic Approaches and Future Directions (7 April 2025) available on‑line in the Hematology/Oncology Clinics of North America (22 May 2025)<br><strong><a href="https://www.sciencedirect.com/science/article/abs/pii/S0889858825000450?via%3Dihub" target="_blank" rel="noopener">https://www.sciencedirect.com/science/article/abs/pii/S0889858825000450?via%3Dihub</a></strong></span></p>
                <p><span class="title-text">Emerging Role of Blood‑based Biomarkers in Sarcomas (2 April 2025) available on‑line in the Hematology/Oncology Clinics of North America (22 May 2025)</span><br><strong><a href="https://www.sciencedirect.com/science/article/abs/pii/S0889858825000401?via%3Dihub" target="_blank" rel="noopener">https://www.sciencedirect.com/science/article/abs/pii/S0889858825000401?via%3Dihub</a></strong></p>
                <p>Myxoid Leiomyosarcoma of the Uterus – A Case Report (2 Apr 2025) in Oncology Letters</p>
                <div><strong><a href="https://pubmed.ncbi.nlm.nih.gov/40230424/" target="_blank" rel="noopener">https://pubmed.ncbi.nlm.nih.gov/40230424/</a></strong></div>
                <div>&nbsp;</div>
                <div><b>Comprehensive mutational profiling identifies new driver events in cutaneous leiomyosarcoma</b> <a href="https://academic.oup.com/bjd/article-abstract/192/2/335/7818451?redirectedFrom=fulltext&login=false" target="_blank" rel="noopener">https://academic.oup.com/bjd/article-abstract/192/2/335/7818451</a></div>
                <div>
                  <p><b>Plain language summary</b></p>
                  <p>Cutaneous leiomyosarcoma (or ‘cLMS’ for short) is a type of skin tumour... These findings give us a better understanding of the biology of cLMS.</p>
                  <p><a href="https://academic.oup.com/bjd/advance-article-abstract/doi/10.1093/bjd/ljae432/7882858?redirectedFrom=fulltext&login=false" target="_blank" rel="noopener">Exploration of the mutational landscape of cutaneous leiomyoma confirms FH as a driver gene</a> &nbsp;&nbsp;&nbsp;<a href="https://doi.org/10.1093/bjd/ljae432" target="_blank" rel="noopener">https://doi.org/10.1093/bjd/ljae432</a></p>
                </div>
                <div>&nbsp;</div>
                <h1><strong>2024</strong></h1>
                <p><b>Dr. Patricia Pautier — research update in the New England Journal of Medicine</b></p>
                <p>Published November 27, 2024<br>N Engl J Med 2024;391:2057-2058<br>DOI: 10.1056/NEJMc2412479</p>
                <p><a href="https://www.nejm.org/toc/nejm/391/21" target="_blank" rel="noopener">VOL. 391 NO. 21</a></p>
                <p><a href="https://www.nejm.org/doi/full/10.1056/NEJMc2412479" target="_blank" rel="noopener">Doxorubicin–Trabectedin in Leiomyosarcoma | New England Journal of Medicine</a></p>
                <p><b>CLINICAL TRIALS:</b></p>
                <p><b>Randomized controlled, open‑label, phase IIb/III study of lurbinectedin in combination with doxorubicin versus doxorubicin alone as first‑line treatment in patients with metastatic leiomyosarcoma.</b> <a href="http://www.clinicaltrials.gov/ct2/show/NCT06088290" target="_blank" rel="noopener">NCT06088290</a></p>
                <p><a href="https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.TPS11590" target="_blank" rel="noopener">Randomized controlled, open‑label, phase IIb/III study of lurbinectedin + doxorubicin vs doxorubicin alone | JCO</a></p>
                <p><b>Study of ADI‑PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)</b></p>
                <p>July 25, 2024 updated by: <a href="https://ichgcp.net/clinical-trials-registry/research/list?spons=Polaris%20Group" target="_blank" rel="noopener">Polaris Group</a></p>
                <p>ADI‑PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects With Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi‑Center Phase 3 Trial</p>
                <p>To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.</p>
                <p><b>Study Overview</b></p>
                <p>This is a global, multicenter, randomized, double‑blind, placebo‑controlled, parallel‑group phase 3 trial...</p>
                <p><a href="http://www.mskcc.org/cancer-care/clinical-trials/24-147" target="_blank" rel="noopener">www.mskcc.org/cancer-care/clinical-trials/24-147</a></p>
                <div><div dir="ltr">Frontiers | Leiomyosarcoma of the abdomen and retroperitoneum; a systematic review (frontiersin.org) &lt;<a href="https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2024.1375483/full" target="_blank" rel="noopener">https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2024.1375483/full</a>&gt;</div></div>
                <div>&nbsp;</div>
                <div>
                  <p>doi: 10.1200/JCO.24.00358<br><b>Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS)</b></p>
                  <p><b>Principle investigator:</b> Dr. Javier Martin–Broto, esteemed member of the NLMSF International LMS Research Roundtable<br><a href="https://pubmed.ncbi.nlm.nih.gov/39356980" target="_blank" rel="noopener">https://pubmed.ncbi.nlm.nih.gov/39356980</a></p>
                  <p><strong>Purpose:</strong> Doxorubicin can induce immunogenic cell death (ICD). Combining doxorubicin and dacarbazine with nivolumab may enhance therapeutic efficacy via ICD synergy. <strong>Conclusion:</strong> The scheme is feasible and well tolerated; clinical activity is encouraging; HMGB1 supports ICD relevance. Further research is underway in LMS.</p>
                </div>
                <p><b>Immunotherapy in Sarcoma: Current Data and Promising Strategies</b><br>
                  <b>Authors</b>: <a href="https://ascopubs.org/doi/10.1200/EDBK_432234#au1" target="_blank" rel="noopener">Georgina E. Wood</a>, <a href="https://ascopubs.org/doi/10.1200/EDBK_432234#au2" target="_blank" rel="noopener">Christian Meyer</a>, <a href="https://ascopubs.org/doi/10.1200/EDBK_432234#con3" target="_blank" rel="noopener">Florent Petitprez</a>, <a href="https://ascopubs.org/doi/10.1200/EDBK_432234#con4" target="_blank" rel="noopener">Sandra P. D’Angelo</a>
                  — <a href="https://ascopubs.org/doi/10.1200/EDBK_432234#tab-contributors" target="_blank" rel="noopener">Authors Info & Affiliations</a><br>
                  <a href="https://ascopubs.org/doi/10.1200/EDBK_432234" target="_blank" rel="noopener">ASCO Educational Book (May 2024)</a>
                </p>
                <div>
                  <div>TRANSLATIONAL CANCER MECHANISMS AND THERAPY | MAY 15 2024</div>
                  <div><b>Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma</b></div>
                  <h4>Josephine K. Dermawan — <i>Clin Cancer Res</i> (2024) 30 (10): 2260–2271.</h4>
                  <h4><a href="https://doi.org/10.1158/1078-0432.CCR-24-0148" target="_blank" rel="noopener">https://doi.org/10.1158/1078-0432.CCR-24-0148</a></h4>
                </div>
                <div>&nbsp;</div>
                <div>Leiomyosarcoma – Continuing Education Activity (28 Feb 2024)</div>
                <div><a href="https://www.ncbi.nlm.nih.gov/books/NBK551667/?__NBK551667_ai__" target="_blank" rel="noopener">https://www.ncbi.nlm.nih.gov/books/NBK551667/</a></div>
                <div>&nbsp;</div>
                <h1><strong>2023</strong></h1>
                <div><span style="font-size: medium;">New therapeutics for soft tissue sarcomas — Overview of current immunotherapy and future directions of STS (14 May 2023)</span></div>
                <div><a href="https://www.frontiersin.org/articles/10.3389/fonc.2023.1150765/full" target="_blank" rel="noopener">Frontiers in Oncology article</a> — Gyuhee Seong and Sandra D’Angelo</div>
                <div>&nbsp;</div>
                <div>
                  <p style="font-weight: 400;">High Grade Sarcomas with Myogenic Differentiation Harboring Hotspot <em>PDGFRB</em> Mutations (May 2023)<br>
                  <a href="https://www.sciencedirect.com/science/article/abs/pii/S089339522300008X" target="_blank" rel="noopener">https://www.sciencedirect.com/science/article/abs/pii/S089339522300008X</a><br>NOTE: LMS discussed in this article</p>
                </div>
                <div><span style="font-size: medium;">The Biology and Treatment of LMS (Apr 2023)</span></div>
                <div><a href="https://www.sciencedirect.com/science/article/pii/S1040842823000434" target="_blank" rel="noopener">https://www.sciencedirect.com/science/article/pii/S1040842823000434</a></div>
                <div>
                  <p style="font-weight: 400;"><strong>Targeting the Molecular and Immunologic Features of Leiomyosarcoma (31 Mar 2023)</strong><br>
                  <a href="https://www.mdpi.com/2072-6694/15/7/2099" target="_blank" rel="noopener"><strong>https://www.mdpi.com/2072-6694/15/7/2099</strong></a></p>
                  <p><strong>Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas</strong> (15 Mar 2023) — MD Anderson<br>
                  <a href="https://pubmed.ncbi.nlm.nih.gov/36603130/" target="_blank" rel="noopener"><strong>https://pubmed.ncbi.nlm.nih.gov/36603130/</strong></a></p>
                  <p style="font-weight: 400;"><strong>Not All Leiomyosarcomas Are the Same: How to Best Classify LMS (8 Mar 2023)</strong> <a href="https://link.springer.com/article/10.1007/s11864-023-01067-2" target="_blank" rel="noopener"><strong>https://link.springer.com/article/10.1007/s11864-023-01067-2</strong></a></p>
                  <p><strong>Therapeutic advances in leiomyosarcoma</strong> (8 Mar 2023) — Frontiers in Oncology<br>
                  <a href="https://www.frontiersin.org/articles/10.3389/fonc.2023.1149106/full" target="_blank" rel="noopener"><strong>https://www.frontiersin.org/articles/10.3389/fonc.2023.1149106/full</strong></a></p>
                </div>
                <div>
                  <p><strong>Clinical characteristics of sarcoma cases with long-term disease control on trabectedin</strong> (1 Mar 2023)<br>
                  <a href="https://pubmed.ncbi.nlm.nih.gov/36857355/" target="_blank" rel="noopener"><strong>https://pubmed.ncbi.nlm.nih.gov/36857355/</strong></a></p>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <!-- Verbatim chunk 2: 2022–2018 and additional items -->
      <div class="elementor-widget-wrap">
        <div class="elementor-element elementor-widget elementor-widget-text-editor">
          <div class="elementor-widget-container">
            <div class="elementor-text-editor elementor-clearfix">
              <div>&nbsp;</div>
              <h1><strong>2022</strong></h1>
              <p><strong>Molecular subtypes of leiomyosarcoma: Moving toward a consensus (2 Nov 2022)</strong><br><a href="https://onlinelibrary.wiley.com/doi/full/10.1002/ctd2.149" target="_blank" rel="noopener">https://onlinelibrary.wiley.com/doi/full/10.1002/ctd2.149</a></p>
              <h3><strong>Landmark Series: A Review of Landmark Studies in the Treatment of Primary Localized Retroperitoneal Sarcoma (2 Nov 2022)</strong> <a href="https://link.springer.com/article/10.1245/s10434-022-12517-w" target="_blank" rel="noopener">https://link.springer.com/article/10.1245/s10434-022-12517-w</a></h3>
              <p><strong>CLINICAL TRIALS: TARGETED THERAPY (2 Aug 2022)</strong><br><strong>Phase II Clinical Trial of Eribulin–Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma</strong><br><a href="https://aacrjournals.org/clincancerres/article-abstract/28/15/3225/707113/Phase-II-Clinical-Trial-of-Eribulin-Gemcitabine?redirectedFrom=fulltext" target="_blank" rel="noopener">https://aacrjournals.org/clincancerres/article-abstract/28/15/3225/707113/...</a></p>
              <p><a href="https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-22-0518/704970/Phase-II-Clinical-Trial-of-Eribulin-Gemcitabine?redirectedFrom=fulltext" target="_blank" rel="noopener"><b>Phase II Clinical Trial of Eribulin–Gemcitabine...</b></a> <strong>(2 Aug 2022)</strong></p>
              <p><a href="https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.11506" target="_blank" rel="noopener">A phase Ib/II study of lenvatinib + eribulin (LEADER): Efficacy updates</a> <strong>(2 Aug 2023)</strong></p>
              <p><a href="https://www.nature.com/articles/s41598-022-16055-z" target="_blank" rel="noopener"><strong>Retroperitoneal LMS Nomogram Model (3 Jul 2022)</strong></a></p>
              <p><a href="https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-22-0738/694390/Sounding-the-Alarm-on-Leiomyosarcoma-Recurrence" target="_blank" rel="noopener"><strong>Sounding the Alarm on Leiomyosarcoma Recurrence: Role of ctDNA</strong></a> (13 Jun 2022)</p>
              <p><strong>PRESS RELEASE NEWS</strong> — UNESBULIN for LMS (3 Jun 2022)</p>
              <p><a href="https://pubmed.ncbi.nlm.nih.gov/35665732/" target="_blank" rel="noopener"><strong>Surgical management strategy for LMS of IVC (3 Jun 2022)</strong></a></p>
              <p><a href="https://aacrjournals.org/clincancerres/article-abstract/28/11/2397/698931/Preclinical-Modeling-of-Leiomyosarcoma-Identifies?redirectedFrom=fulltext" target="_blank" rel="noopener"><strong>Preclinical Modeling of LMS Identifies Susceptibility to Transcriptional CDK Inhibitors</strong></a> — Dr. Matt Hemming (1 Jun 2022)</p>
              <p><strong>Preoperative Differentiation of Uterine Leiomyomas and Leiomyosarcomas</strong> (13 Apr 2022)<br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029111/" target="_blank" rel="noopener">Full publication</a></p>
              <p><a href="https://leiomyosarcoma.info/wp-content/uploads/2022/03/Kasper2022_Article.pdf" target="_blank" rel="noopener">What Clinical Trials Are Needed for Treatment of Leiomyosarcoma?</a> (11 Mar 2022)</p>
              <p><a href="https://link.springer.com/article/10.1007/s11864-022-00947-3" target="_blank" rel="noopener">Proteomic and Metabolomic Profiling in STS</a> (16 Feb 2022)</p>
              <div>&nbsp;</div>
              <h1><strong>2021</strong></h1>
              <p><a href="https://pubmed.ncbi.nlm.nih.gov/34710646/" target="_blank" rel="noopener">Surgical resection of LMS of the IVC: case series + review</a></p>
              <p><a href="https://pubmed.ncbi.nlm.nih.gov/33788262/" target="_blank" rel="noopener">Relationships between highly recurrent tumor suppressor alterations in 489 LMS</a></p>
              <p><a href="https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.11512" target="_blank" rel="noopener">Large scale multiomic analysis suggests mechanisms of resistance to IO in LMS</a></p>
              <p><a href="https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.11555" target="_blank" rel="noopener">Multiomic analysis to reveal distinct profiles of uterine and non‑uterine LMS</a></p>
              <ul>
                <li><a href="https://pubmed.ncbi.nlm.nih.gov/33941787/" target="_blank" rel="noopener">Hexosamine biosynthesis pathway prognostic relevance</a> and <a href="https://www.nature.com/articles/s41525-021-00193-w" target="_blank" rel="noopener">companion article</a></li>
                <li><a href="https://youtu.be/8DN8YhJWxvM" target="_blank" rel="noopener">Dr. Matt Hemming’s Presentation</a></li>
                <li><a href="https://www.researchgate.net/publication/330615358_Detection_of_Circulating_Tumor_DNA_in_Patients_With_Leiomyosarcoma_With_Progressive_Disease" target="_blank" rel="noopener">2019 Research article publication</a></li>
                <li><a href="https://youtu.be/a98XOq_BE6k" target="_blank" rel="noopener">Dr. Brian Crompton and Dr. Jonathan Trent Presentations</a></li>
                <li><a href="https://www.researchgate.net/publication/343495968_Identification_of_Genetic_Alterations_by_Circulating_Tumor_DNA_in_Leiomyosarcoma_A_Molecular_Analysis_of_73_Patients" target="_blank" rel="noopener">ctDNA in LMS — 73 Patients</a></li>
              </ul>
              <div>&nbsp;</div>
              <h1><strong>2020</strong></h1>
              <ul>
                <li><a href="http://pubmed.ncbi.nlm.nih.gov/32211860" target="_blank" rel="noopener">Current explorations of nutrition and the gut microbiome</a></li>
                <li><a href="https://www.onclive.com/view/sarcoma-experts-elucidate-on-combination-chemotherapy-regimens" target="_blank" rel="noopener">Sarcoma Experts: Combination Chemotherapy Regimens</a></li>
                <li><a href="https://pubmed.ncbi.nlm.nih.gov/31439678/" target="_blank" rel="noopener">Genomic profiling of primary histiocytic sarcoma</a></li>
                <li><a href="https://www.mdlinx.com/journal-summary/a-phase-ii-study-of-pazopanib-as-front-line-therapy-in-patients-with-non-resectable-or-metastatic/SrMG4YmQYOl6QDUaKw5xy?news_id=795" target="_blank" rel="noopener">Pazopanib front‑line in non‑resectable/metastatic STS</a></li>
                <li><a href="https://www.clinicaloncology.com/Sarcoma/Article/11-20/Risk-Score-Helps-Guide-Patient-Selection-for-Resection-of-Sarcoma-Lung-Metastases/61132" target="_blank" rel="noopener">Risk Score for Lung Metastases Resection in Sarcoma</a></li>
                <li><a href="https://pubmed.ncbi.nlm.nih.gov/32299819/" target="_blank" rel="noopener">Genomic Landscape of Uterine Sarcomas — Prospective sequencing</a></li>
              </ul>
              <div>&nbsp;</div>
              <h1><strong>2019</strong></h1>
              <p><b>Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma</b><br><a href="https://pubmed.ncbi.nlm.nih.gov/31164371/" target="_blank" rel="noopener">PubMed</a> &nbsp;|&nbsp; <a href="https://aacrjournals.org/clincancerres/article/25/16/5135/264451/Genomic-Evolutionary-Patterns-of-Leiomyosarcoma" target="_blank" rel="noopener">Clinical Cancer Research</a></p>
              <ul>
                <li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656468/" target="_blank" rel="noopener">BRCA 1/2 Functional Loss Defines a Targetable Subset in LMS</a></li>
                <li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380497/" target="_blank" rel="noopener">ctDNA in LMS with Progressive Disease</a></li>
              </ul>
              <div>&nbsp;</div>
              <h1><strong>2018</strong></h1>
              <p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759317/" target="_blank" rel="noopener">Soft Tissue and Uterine Leiomyosarcoma</a> (10 Jan 2018)</p>
              <ul>
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/31068995" target="_blank" rel="noopener">Cutaneous LMS on the trunk — aggressive course case</a></li>
                <li><a href="https://www.targetedonc.com/publications/targeted-therapy-news/2017/July-2017/separating-treatment-of-leiomyosarcomas-from-sts-umbrella" target="_blank" rel="noopener">Treating LMS separately from other STS</a></li>
                <li><a href="https://jcp.bmj.com/content/70/10/879" target="_blank" rel="noopener">HIF‑1α predicts recurrence in high‑grade STS</a></li>
                <li><a href="https://www.mdlinx.com/journal-summaries/alt-sarcoma-mesenchymal-prognosis-survival-atr/2019/03/15/7560777/ZZF2A96C33183244818892F163F267E094" target="_blank" rel="noopener">ALT influences survival in STS — meta‑analysis</a> | <a href="https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5424-8" target="_blank" rel="noopener">Full Text</a></li>
                <li><a href="https://www.hindawi.com/journals/sarcoma/2019/3914232/" target="_blank" rel="noopener">CDK4/6 pathway in LMS — Palbociclib</a></li>
                <li><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617490/" target="_blank" rel="noopener">PDOX model identifies effective therapies for recurrent LMS</a></li>
              </ul>
            </div>
          </div>
        </div>
      </div>
    </details>
  </section>
</div>
